



Citation for the published version:

Dawoud, N. M., Ayoub, O. H., Essa, E. S., & Dawoud, D. M. (2018). Myelodysplasia in a psoriasis patient receiving etanercept: Cause or coincidence? *Indian journal of dermatology, venereology and leprology*, 84(4), 463-465. DOI: 10.4103/ijdvl.IJDVL_463_17

Document Version: Accepted Version

Link to the final published version available at the publisher:

https://doi.org/10.4103/ijdvl.IJDVL_463_17

General rights

Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners.

Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<http://uhra.herts.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Take down policy

If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.

Enquiries

Please contact University of Hertfordshire Research & Scholarly Communications for any enquiries at rsc@herts.ac.uk

Technical Editing by Sinjore Technologies: 17-01-2018

<RH>Letter to the Editor

Letter to the Editor

Myelodysplasia in a psoriasis patient receiving etanercept: Cause or coincidence?

Sir,

Myelodysplastic syndrome comprises hemopoietic insufficiency, often associated with cytopenias of one or more cell lineages that may lead to leukemic transformation.¹ Here, we report a case of myelodysplastic syndrome in a psoriatic patient following therapy with tumour necrosis factor- α blocking agent (etanercept).

A 76-year-old male patient presented with psoriasis vulgaris since the last 20 years without any arthritis. He was treated with subcutaneous etanercept, 50 mg twice a week for 6 months followed by once a week for another 6 months, to achieve Psoriasis Area and Severity Index 90 (PASI90) at 6 months. Prior to etanercept he had been treated with topical steroids, topical vitamin D analogues, 6-month course of narrow-band-ultraviolet-B and 1-year acitretin without any appreciable benefit.

After one year of etanercept therapy, the patient presented to our emergency unit with spontaneous bluish bruising (ecchymosis) and recurrent epistaxis. A complete blood count recorded critically low platelet count ($23 \times 10^9/L$), anemia (11.7 g/dl) and normal leukocyte count ($6.6 \times 10^9/L$), with $0.5 \times 10^9/L$ monocytes and 2% blasts [Figure 1]. Reticulocyte count was 136×10^3 cells/mm³, 3.4% ($N = 0.8-2.5\%$) with low reticulocyte index, serum ferritin was

1280 ng/ml ($N = 21.8\text{--}274.7$ ng/ml) and folate was low at 1.7 ng/ml ($N = 7\text{--}31.4$ ng/ml), which indicated ineffective erythropoiesis. (Table 1)

Bone marrow aspirate [Figure 2] and biopsy [Figure 3] revealed hypercellularity. Blast cells accounted for almost 8% of the total nucleated marrow cells. The majority of neutrophils were hypogranular. Hypolobulated megakaryocytes were observed. Reticulin fibres were not increased.

Peripheral blood also revealed bicytopenia, blasts and $0.5 \times 10^9/L$ monocytes. Bone marrow showed 8% trilineage dysplasia and blasts. A diagnosis of myelodysplastic syndrome with excess blasts-1 was made based on the hematologic picture.

We stopped etanercept treatment and administered two cycles of azacitidin and folic acid supplementation, with almost no response and even worsening of platelet count ($17 \times 10^9/L$) and hemoglobin (8.3 g/dl). While he was waiting for the third cycle, he was admitted to the emergency unit suffering from lower gastrointestinal bleeding, epistaxis and shock. The patient expired eventually due to cardiopulmonary arrest.

Immune dysregulation and altered T-cell hemostasis are essential factors for the development of myelodysplastic syndrome. Several authors have reported a higher risk of myelodysplastic syndrome in patients suffering from autoimmune disorders, resulting from chronic overproduction of apoptosis inducing cytokines like tumor necrosis factor-alpha. It has been proven that accelerated apoptosis of bone marrow cells accounts for the disturbed hemopoiesis and peripheral blood cytopenias leading to myelodysplastic syndrome, despite the presence of hypercellular bone marrow.¹ In addition, nonspecific activation and proliferation of T

lymphocytes seen in myelodysplastic syndrome has been documented to promote epidermal growth in genetically susceptible psoriasis patients.²

Myelodysplastic syndrome may be associated with psoriasis in about 7% of cases.³ Özbek *et al.* reported a 3.5-year-old girl with psoriasis, hypogammaglobulinemia and pancytopenia who developed myelodysplastic syndrome-excess blasts that progressed to acute myeloid leukemia.² Moreover, Maleszka *et al.* noted increased incidence of leukemia and laryngeal cancer among families of psoriasis patients.⁴ In addition, there are some reported cases of leukemia that developed in psoriasis patients receiving systemic immunosuppressives (cyclosporine, methotrexate and etanercept). However, the association of leukemia and psoriasis is not well-investigated.⁴

Etanercept may induce various hematological side effects including pancytopenia and aplastic anaemia, as reported by the US Food and Drug Administration.⁵ Tumor necrosis factor-alpha enforces apoptosis of tumor cells and promotes different antitumor activities like activation of natural killer cells, stimulation of CD8 cells and acceleration of camptothecan and etoposide antitumor effect. Loss of such activities may mediate tumor growth in acute and chronic myeloid leukemia.⁶

Tumor necrosis factor-alpha is also inhibitory to hematopoietic stem cells. Studies have shown increased levels of tumor necrosis factor-alpha in myelodysplastic syndrome marrow. Thus, antagonizing it significantly enhances *in-vitro* hematopoietic colony formation. Deeg *et al.* tried to treat myelodysplastic syndrome with etanercept as a pilot trial.⁷ However, their study found limited favorable response in some patients and worsening of blood cell counts in others. The findings of Deeg *et al.* and the contradictory effects of tumor necrosis factor-alpha on dysplastic

bone marrow suggest that tumor necrosis factor-alpha is only partially accountable for the dysregulated hemopoiesis in myelodysplastic syndrome; thus there are various other pathomechanisms for myelodysplastic syndrome.⁷

Only three cases of myelodysplastic syndrome have been reported till date in psoriasis patients following etanercept therapy, ours being the 4th case. Nair *et al.* reported the case of a 57-year-old man with psoriatic arthritis who developed myelodysplasia that progressed to acute myeloid leukemia after 6 months of etanercept treatment.⁶ Bachmeyer *et al.*⁸ and Knudson *et al.*⁹ reported the cases of 40 and 43-year-old psoriatic males who were diagnosed with myelodysplastic syndrome after 4 and 14 months of etanercept therapy, respectively. The case reported by Knudson *et al.* had progressed to acute myeloid leukemia followed by death.⁹ In addition to the aforementioned cases, another case was reported by Bakland and Nossent where a 31-year-old female with ankylosing spondylitis developed acute myeloid leukemia 4 months after etanercept treatment.⁵ In our case, myelodysplasia with excess blasts developed 1 year after initiating etanercept therapy.

Taken together, the current case adds to the growing evidence that suggests a link between myelodysplastic syndrome and etanercept treatment in psoriasis patients. Pre-treatment thrombocytopenia was seen in our patient ($131 \times 10^9/L$) and the patient reported by Knudson *et al.* patient ($126 \times 10^9/L$)⁹, while mild leucopenia ($3.6 \times 10^9/L$) was reported by Bakland and Nossent before initiation of etanercept.⁵ More studies are needed to clarify whether this was an accidental association or etanercept may aggravate myelodysplasia in all susceptible patients.

Although progressive and critical worsening of blood counts following etanercept treatment may demonstrate its aggressive hematologic and myelodysplastic adverse events, the susceptibility of

psoriasis patients to myelodysplasia cannot be ruled out. Therefore, the present case and literature review support the need for pharmacovigilance, prospective cohort or retrospective case-control studies to prove or disprove this association.

In conclusion, psoriatic patients being treated with etanercept should be considered at dual risk of developing myelodysplastic syndrome – therapy-related and autoimmunity-associated. Hence, we recommend that psoriatic patients who are receiving etanercept should be followed regularly by routine blood counts and it should be discontinued upon onset of any cytopenias.

<H2>Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his ~~images and other~~ clinical information to be reported in the journal. The patient understand that name and initials will not be published ~~and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.~~

<H2>Financial support and sponsorship

Nil.

<H2>Conflicts of interest

There are no conflicts of interest.

**Noha Mohammed Dawoud^{1,2}, Othman Hadi Ayoub³, Enas Said Essa⁴, Dalia Mohammed
Dawoud⁵**

Departments of ¹Dermatology, Andrology and STDs and ⁴Clinical Pathology, Faculty of
Medicine, Menoufia University, ~~Minufiyah~~ **Menoufia**, ⁵Department of Clinical Pharmacy,

Faculty of Pharmacy, Cairo University, Giza, Egypt, Departments of ²Dermatology and ³Hematology, Al Hada Armed Forces Hospital, Al Hada Taif, Kingdom of Saudi Arabia

Correspondence: Dr. Noha Mohammed Dawoud,
Department of Dermatology, Al Hada Armed Forces Hospital, Taif 21944, PO Box 1347,
Kingdom of Saudi Arabia.

E-mail: dr_ndawoud@yahoo.com

Received: August, 2018. **Accepted:** January, 2018.

How to cite this article: Dawoud NM, Ayoub OH, Essa ES, Dawoud DM. Myelodysplasia in psoriasis patient receiving etanercept: Cause or coincidence? Indian J Dermatol Venereol Leprol XX;XX:XX.

<H1>References

1. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia-associated autoimmunity: Clinical and pathophysiologic concepts. Eur J Clin Invest 2004;34:690-700.
2. Özbek N, Yazal Erdem A, Arman Bilir Ö, Karaca Kara F, Yüksek M, Yaralı N, *et al.* A child with psoriasis, hypogammaglobulinemia, and monosomy 7-positive myelodysplastic syndrome. Turk J Haematol 2015;32:87-8.
3. Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, *et al.* Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 2016;91:E280-3.

4. Maleszka R, Paszkowska-Szczur K, Soczawa E, Boer M, Różewicka-Czabańska M, Wiśniewska J, *et al.* Psoriasis vulgaris and familial cancer risk- a population-based study. *Hered Cancer Clin Pract* 2013;11:6.
5. Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. *Rheumatology (Oxford)* 2003;42:900-1.
6. Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature. *Am J Hematol* 2007;82:1022-4.
7. Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, *et al.* Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. *Leukemia* 2002;16:162-4.
8. Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. *J Am Acad Dermatol* 2007;56:169-70.
9. Knudson RM, Tefferi A, Pittelkow MR, Davis MD. Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. *J Am Acad Dermatol* 2011;65:673-4.

Table

Table 1: Retrospective analysis for complete blood count of the reported case

CBC (reference range and unit)	Baseline	During etanercept treatment		After stoppage of etanercept		
		6 months	12 months	1 month	With use of azacitidine	
					2 months	4 months
Hemoglobin (14.0–18.0 g/dl)	17.6	15.8	11.7	11.0	9.2	8.3
White blood cells (3.0–11.0×10 ⁹ /L)	9.4	6.0	6.6	21.0	9.0	7.3
Neutrophils (2.0–7.0×10 ⁹ /L)	6.5	4.0	4.9	16.0	6.8	3.8
Lymphocytes (1.0–3.0×10 ⁹ /L)	1.1	0.9	0.9	2.5	0.9	1.7
Monocytes (0.2–1.0×10 ⁹ /L)	1.2	0.9	0.5	0.8	0.9	0.9
Eosinophils (0.02–0.5×10 ⁹ /L)	0.01	0.0	0.0	0.0	0.0	0.03
Basophils (0.02–0.1×10 ⁹ /L)	0.64	0.2	0.1	1.3	0.2	0.65

Blast ($0.0 \times 10^9/L$)	0.0	0.0	0.1	0.4	0.2	0.2
Platelet (150– $450 \times 10^9/L$)	131	70	23	23	17	17
CBC: Complete blood count						

Figure Legends

Figure 1a: Peripheral blood smear showing monocytes (black arrow) ($\times 100$)

Figure 1b: Peripheral blood smear showing blast cells (red arrow) (oil immersion) ($\times 100$)

Figure 2: Bone marrow smear showing hypercellular bone marrow with hypolobated megakaryocytes (arrow and inset \times oil immersion) ($\times 400$ 40)

Figure 3: Bone marrow trephine biopsy showing hypolobated megakaryocyte (red arrow) and a cluster of abnormal localization of immature precursors (blue arrow) ($\times 400$ 40)